Highlights

  • Ansell (ASX:ANN) reported FY26 sales of USD 2,140.2 million.
  • FY26 adjusted EBIT was USD 321.9 million; statutory NPAT was USD 208.6 million.
  • Operating cash flow reached USD 270.1 million in FY26.
  • Management guided to FY27 adjusted EPS of US 158–170 cents.

Ansell manufactures protective gloves, clothing and related safety products for industrial workplaces, hospitals and other specialist environments worldwide. Ansell (ASX:ANN) closed at AUD 46.40 on November 18, 2026, edging down 0.19% during the session. Its FY26 results described sales growth, higher adjusted earnings, greater Operating Cash Flow and an updated Earnings range for the following financial year.

Industrial and Healthcare Markets

Ansell supplies personal protective equipment across two main reporting segments: Industrial and Healthcare. Industrial products include mechanical and chemical protection, while Healthcare serves examination, surgical and cleanroom requirements. The company distributes products through multiple geographic markets, exposing sales and production costs to global demand, Manufacturing conditions and exchange rates. Understanding the mix matters because growth in laboratory and cleanroom products may occur on a different cycle from broad industrial glove demand.

FY26 Sales and Earnings

For the year ended June 30, 2026, Ansell announced sales of USD 2,140.2 million, an increase of 6.8% on a reported basis. Adjusted EBIT was USD 321.9 million, while statutory EBIT reached USD 320.5 million. Statutory net profit after tax was USD 208.6 million and adjusted NPAT was USD 212.3 million. These adjusted and statutory figures reflect different treatment of significant items and should not be conflated. Management reported adjusted Earnings Per Share of US 148.6 cents. Industrial segment adjusted EBIT was USD 170.6 million, compared with USD 170.7 million for Healthcare. Both segment profitability and group results help explain the company’s earnings composition.

Cash Flow and Shareholder Returns

Ansell recorded FY26 operating cash flow of USD 270.1 million under its reported definition. It completed USD 118.4 million of Buybacks during the year as part of an existing USD 200 million on-market program. The company declared a final unfranked dividend of US 41.5 cents, bringing full-year dividends to US 68.1 cents per share. It also reported net Debt to adjusted EBITDA of 1.3 times at June 30. Cash generated during FY26 supported buybacks and debt reduction, but future Capital distributions depend on financial performance and board decisions. These figures are historical outcomes, not assurances of future payments.

Costs, Productivity and Outlook

Ansell described price increases and sourcing changes implemented to address tariffs and higher Supply costs. Its Accelerated Productivity Investment Program reached a targeted USD 50 million of recurring pretax savings, while technology-system upgrades remain part of the next stage. The FY27 adjusted EPS guidance range was US 158 to 170 cents, compared with US 148.6 cents in FY26. Ansell (ASX:ANN) is also continuing a previously announced buyback program, which can affect per-share calculations.

Monitoring and Key Insights

Future reporting should show sales Volume and pricing by segment, profitability from product mix, cash conversion and the cost of technology-system implementation. Investors can assess whether actual FY27 adjusted EPS falls within the range communicated in August, without assuming that it will. Ansell (ASX:ANN) entered FY27 with higher reported FY26 sales, profit and operating cash flow, but the Business remains exposed to industrial Demand and procurement conditions in healthcare. Distinguishing statutory earnings, adjusted metrics and cash flow provides a more complete financial view than focusing on any single headline figure. Its FY27 outlook is an estimate requiring subsequent confirmation.